Clinical Trial Update: Evaluation of the Safety and Effectiveness of Tailored Transoral Incisionless Fundoplication (TIF) Using EsophyX for the Treatment of GERD [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Tailored Transoral Incisionless Fundoplication (TIF) using the EsophyX device for gastroesophageal reflux disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• EsophyX

Snippet

Sponsor: University of Alberta | Conditions: Gastroesophageal Reflux Disease (GERD) | Phase 2 | Status: WITHDRAWN